Retrospective real-world clinical study of PD-1 monoclonal antibody for advanced hepatocellular carcinoma

Retrospective real-world clinical study of programmed cell death factor 1 monoclonal antibody for advanced hepatocellular carcinoma

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100047779

Enrollment

Unknown

Registered

2021-06-26

Start date

2021-06-22

Completion date

Unknown

Last updated

2022-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma (HCC)

Interventions

Case series:No

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Histologically confirmed or clinically diagnosed hepatocellular carcinoma; 2. Patients who were treated with PD-1 monoclonal antibody for >=2 months with at least one efficacy evaluation data; 3. For the screening of patients who survived fashion in this study, whether the patients themselves or their legal representatives should sign the informed consent shall be decided by the ethics committee of each research center; 4. For patients who died or lost contact at the time of screening in this study, there is no need to sign the informed consent, and the researchers are responsible to keep the data of such patients confidential.

Exclusion criteria

Exclusion criteria: Incomplete data affect the judgment of efficacy and safety.

Design outcomes

Primary

Measure	Time frame
Progression-free survival;	—

Secondary

Measure	Time frame
Overall survival;Objective response rate;Disease control rate;Quality of life score;	—

Countries

China

Contacts

Public ContactSun Huichuan

Zhongshan Hospital affiliated to Fudan University

Sun.huichuan@zs-hospital.sh.cn+86 13701922065

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026